Summary
Eli Lilly and Company reported $5.60 billion in revenue for the first quarter of 2012, a decrease of 4% compared to the same period in 2011. This decline was primarily attributed to the loss of patent exclusivity for its drug Zyprexa, which significantly impacted sales. Despite the revenue dip, net income remained strong at $1.01 billion, though it was down 4% year-over-year, resulting in diluted earnings per share of $0.91. The company's strategic focus remains on growing its patent-protected products, expanding in emerging markets and Japan, and advancing its animal health business to offset patent expirations. Lilly also highlighted its robust late-stage pipeline with several new molecular entities in Phase III trials across various therapeutic areas. Operationally, research and development expenses increased slightly to $1.15 billion, supporting its ongoing drug development efforts. The company also addressed a significant increase in its effective tax rate to 24.3% from 17.1% in the prior year, partly due to the absence of certain tax benefits. Lilly maintained a strong liquidity position with $4.12 billion in cash and cash equivalents as of March 31, 2012, and reiterated its commitment to dividends and its ongoing share repurchase program, although no shares were repurchased in Q1 2012.
Financial Highlights
49 data points| Revenue | $5.60B |
| Cost of Revenue | $1.20B |
| Gross Profit | $4.40B |
| R&D Expenses | $1.15B |
| SG&A Expenses | $1.85B |
| Operating Expenses | $3.00B |
| Interest Expense | $45.30M |
| Net Income | $1.01B |
| EPS (Basic) | $0.91 |
| EPS (Diluted) | $0.91 |
Key Highlights
- 1Revenue declined 4% year-over-year to $5.60 billion, primarily due to the loss of patent exclusivity for Zyprexa.
- 2Net income decreased 4% to $1.01 billion, with diluted EPS at $0.91.
- 3Research and development expenses increased 2% to $1.15 billion, signaling continued investment in pipeline development.
- 4The effective tax rate increased significantly to 24.3% from 17.1% in the prior year.
- 5Cash and cash equivalents stood at $4.12 billion as of March 31, 2012, indicating a solid liquidity position.
- 6The company is actively managing patent expirations by focusing on growth in protected products, emerging markets, and its animal health segment.
- 7Multiple late-stage pipeline assets are in Phase III trials, offering future growth potential.